Evaluation of Natriuretic Peptide in Non-small Cell Lung Cancer Patients Treated with Bevacizumab Together with Carboplatin–Paclitaxel: A Prospective Study
- TOMOYUKI OTSUKA1,2,
- TAKASHI NOJIRI3,4,
- SEIGO MINAMI5,
- HIROSHI HOSODA6,
- MUNEYOSHI KUROYAMA1,
- HARUHIKO HIRATA1,
- KAORI NAKANISHI7,8,
- SUGURU YAMAMOTO5,
- KIYOSHI KOMUTA5,
- KENJI KANGAWA3 and
- TAKASHI KIJIMA1⇑
- 1Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
- 2Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan
- 3Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
- 4Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
- 5Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan
- 6Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
- 7Health Care Center, Osaka University, Toyonaka, Japan
- 8Department of Respiratory Medicine, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, Itami, Japan
- Correspondence to: Takashi Kijima, MD, Ph.D., Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. Tel: +81 668793833, Fax: +81 668793839, e-mail: tkijima{at}imed3.med.osaka-u.ac.jp
Abstract
Aim: To identify predictive markers for efficacy of combination bevacizumab and carboplatin-paclitaxel treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Patients and Methods: Twenty patients received carboplatin (area under the concentration-time curve (AUC) 6 mg/ml×min) and paclitaxel (200 mg/m2) with bevacizumab (15 mg/kg) on day 1 of a 21-day cycle. After four cycles of induction therapy, patients received bevacizumab maintenance therapy until disease progression or unacceptable toxicity occurred. Plasma and serum samples (baseline, day 8 and before cycle 2) were analyzed for natriuretic peptide content. Results: Plasma brain natriuretic peptide (BNP) levels were significantly decreased at day 8 (20.1±4.0 pg/ml vs. 9.1±1.8 pg/ml, p=0.0002). Patients whose plasma BNP level was reduced to <50% of the baseline at day 8 had a longer progression-free survival (PFS) than those with a less decrease (9.73 versus 2.63 months, p=0.00013). In multivariate Cox analysis, decrease of plasma BNP concentration was associated with a longer PFS (p=0.0022). Conclusion: Decrease of plasma BNP concentration correlated with PFS after a treatment of combination bevacizumab plus carboplatin-paclitaxel.
- Received May 26, 2017.
- Revision received June 8, 2017.
- Accepted June 9, 2017.
- Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
